About
Epigenetic Drug Discovery
Areas of Focus
Categories
Drug Delivery & FormulationBoston & New England
Team (61)
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
585
By Phase
PHASE2: 1PHASE1/PHASE2: 2
By Status
NOT_YET_RECRUITING: 2RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07096778Lead Sponsor
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
PHASE2Not yet recruiting
100 participants
Started: Dec 1, 2025 · Completed: Dec 1, 2029
NCT06322927Collaborator
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
N/ANot yet recruiting
15 participants
Started: Mar 31, 2024 · Completed: Sep 30, 2024
NCT04068597Lead Sponsor
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
PHASE1/PHASE2Recruiting
250 participants
Started: Aug 9, 2019 · Completed: Mar 31, 2027
NCT03568656Lead Sponsor
Study to Evaluate CCS1477 in Advanced Tumours
PHASE1/PHASE2Completed
220 participants
Started: Jul 23, 2018 · Completed: Jul 6, 2025
Locations (1)
Headquarters
Burlington, MA, United States
Map
Loading map...